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Objective: The clinical descriptionof anovelTTRgenemutation characterizedbya lateonset amyloid cardiomyopathy.
Methods andResults:A78-year-oldmanofDutchoriginwith recent surgery for bilateral carpal tunnel syndrome(CTS)
was admitted to our hospital because of heart failure with preserved ejection fraction (55%). Cardiac ultrasound
showed thickened biventricular walls, and cardiac magnetic resonance imaging also showed late gadolinium en-
hancement. Early signs of a polyneuropathy were found by neurophysiological testing. A few months later, his 72-
year-old sister was admitted to an afﬁliated hospital because of heart failure caused by a restrictive cardiomyopathy.
In both patients, a subcutaneous abdominal fat aspiratewas stainedwith Congo red and DNAwas analyzed by direct
sequencing of exons 1 to 4 of the transthyretin (TTR) gene. Both fat aspirates revealed transthyretin-derived (ATTR)
amyloid. 99mTc-diphosphonate scintigraphy further conﬁrmed cardiac ATTR amyloidosis in the male patient. DNA
analysis of both patients showed a novel TTRmutation c.194C N G that encodes for the gene product TTR (p.A65G)
ending up as themature protein TTRA45G. The 56-year-old daughter of themale patient had the same TTRmutation.
A full diagnostic workup did not reveal any signs of amyloidosis yet.
Conclusions:Anovel amyloidogenic TTRmutationwas found in aDutch family. The clinical presentationof ATTRA45G
amyloidosis in the affected family members was heart failure due to a late-onset cardiomyopathy. The systemic na-
ture of this disease was reﬂected by bilateral CTS and by early signs of a polyneuropathy in the index patient.
© 2017 Elsevier Inc. All rights reserved.1. Introduction
The etiology of hereditary transthyretin-derived (ATTR) amyloidosis
is the deposition of amyloid ﬁbrils in the extracellular matrix due to mu-
tations of the gene encoding transthyretin (TTR). More than 110 TTRmu-
tations have been associated with hereditary ATTR amyloidosis [1,2].
Disease presentation, severity, and clinical course of ATTR amyloidosis
are variable. Usually the disease starts with the clinical picture of a
polyneuropathy accompanied by autonomic neuropathy, but sometimes,
a cardiomyopathy is the presenting manifestation. In addition, albeit lesseciﬁc grant from funding agen-
e, Atrial Fibrillation, Genetics
University Medical Center Gro-
rlands. Tel.: +31-503613432;
n).frequent, other organs can be affected leading to carpal tunnel syndrome
(CTS), vitreous opacities, or loss of renal function [1–3]. Clinical course
and disease severity vary among differentmutations [4]. Despite an initial
monosymptomatic presentation, other organ involvement usually de-
velops during disease progression. In the current report, we describe a
Dutch family with a novel TTRmutation with late-onset cardiomyopathy,
that is, not symptomatic before the sixthdecade [5]. Although cardiac pre-
sentation was the prominent feature, a recent history of bilateral CTS and
preclinical involvement of the peripheral nervous system were recog-
nized in one of the two cases reﬂecting the systemic nature of the disease.
2. Patients and methods
A 78-year-oldman and his 72-year-old sister, both knownwith atri-
al ﬁbrillation (AF), presented with symptoms of heart failure at a hospi-
tal a couple of months after each other. Amyloidosis was considered a
possible cause; consequently, a subcutaneous abdominal fat tissue aspi-
rate was obtained that showed the presence of amyloid in both cases,
20 S.HC. Klaassen et al. / Cardiovascular Pathology 29 (2017) 19–22and subsequently, both cases were referred to our Amyloidosis Center
of Expertise. A 56-year-old daughter of the male patient was referred
later for clinical investigation.
Ample (more than 100 mg) subcutaneous abdominal fat tissue was
aspirated using a 16-Gauge needle. Amyloid was extracted in 6-M gua-
nidine hydrochloride and further analyzed as described [6]. The TTR
concentration in fat tissue of the extracted amyloidwas assessed immu-
nochemically using an indirect enzyme-linked immunosorbent assay
[7] and also chemically by proteomics using a selected reaction-moni-
toring-mass spectrometry assay (SRM-MS; kindly provided by Paula
Picotti and Paul Boersema, Zürich, Switzerland). The amount of Congo
red-stained birefringent material was assessed semiquantitatively [8].
DNAwas analyzed in all cases by direct sequencing of exons 1 to 4 of
the TTR gene. The primary translation product is 20 amino acids longer
than themature TTR protein because the signal peptide and propeptides
are included. This leads to amino acid position numbers of the transla-
tion product that are 20 higher than those of the correspondingmature
protein [2].
A full clinical investigation to detect other organs affected by amy-
loid was offered to all patients. Due to the observational nature of this
study, according to Dutch law, informed consent and permission of
the local institutional review board were not required.
3. Results
3.1. Case 1
A 78-year-old man, known with AF for the last 2 years, presented
with symptoms of heart failure at our hospital. Plasma levels of NT-
proBNP and hs-Troponin T were 1877 ng/l (Nb125) and 48 ng/l
(Nb14), respectively. One year before, he suffered from CTS in both
hands, which was successfully treated by surgery. His electrocardio-
gram showed AF, low-voltage QRS complexes, and a left anterior fascic-
ular block. A 24-h rhythmmonitoring did not reveal other arrhythmias.
Echocardiography showed concentric left ventricular wall hypertrophy
and a left ventricular ejection fraction (EF) of 55%. Hypertrophy of the
right ventricular wall (7 mm) was also observed. A multigated acquisi-
tion scan showed a left ventricular EFN65% and a right ventricular EF of
44%. Cardiac magnetic resonance (CMR) imaging showed late gadolini-
um enhancement and a thickened interventricular septum (18 mm).
Based on these clinical ﬁndings, amyloidosis was considered to be pres-
ent. Easily accessible subcutaneous abdominal fat tissue was aspirated
as screening biopsy for amyloidosis. The tissue was stained with
Congo red, which indeed showed the presence (abundant, visual
grade 4+) of amyloid (Fig. 1) [8]. No signs of immunoglobulin free
light chain overproduction (serum kappa free light chain 13.1 mg/l
(Nb20) and lambda free light chain 13.0 mg/l (Nb32)) nor other signs
of a plasma cell dyscrasia were found in serum, urine, or bone marrow.Fig. 1. Congo red-stained ﬁne needle aspiration of abdominal fat tissue of Case 1. (These ﬁndings made light chain-derived systemic AL amyloidosis very
unlikely. The creatinine clearance was 74 ml/min, and no proteinuria
was observed. 123I–Serum Amyloid P component (SAP) scintigraphy
showed some splenic uptake, whereas 99mTc-diphosphonate bone scin-
tigraphy showed strongly increased (3+) cardiac uptake (Fig. 2) [9].
123I–metaiodobenzylguanidine (123I–MIBG) scintigraphy showed an in-
creased washout (34%) and low heart–mediastinum ratio (late uptake
1.16) indicative of cardiac denervation [10]. A ﬁne needle subcutaneous
abdominal fat aspirate yielded a TTR concentration of amyloid in fat of
658-ng/mg fat tissue (Nb7.5 ng/mg) [6,7]. These ﬁndings indicated
ATTR amyloidosis to be present. Wild-type ATTR amyloidosis was ex-
cluded because subsequent TTR gene analysis showed a novel mutation
c.194C N G that encodes the primary translation product (p.A65G) and
the mature protein TTR A45G [11]. SRM-MS proteomics conﬁrmed the
speciﬁc TTR mutation in the amyloid extracted from fat tissue. The pa-
tient was therefore diagnosed with hereditary ATTR A45G amyloidosis
with prominent cardiac involvement and CTS. He had not noticed any
symptoms of peripheral or autonomic neuropathy. Neurophysiological
testing, however, revealed an early-stage length-dependent axonal sen-
sory polyneuropathy in the feet of the patient. Quantitative sensory test-
ing of the ankle also showed thin ﬁber neuropathy. Hewas treatedwith
the TTR tetramer-stabilizing drug tafamidis for his polyneuropathy [12],
and the clinical condition of both his heart and nerves seemed to stabi-
lize during the next 2 years of follow-up.
3.2. Case 2
Family history of Case 1 revealed that the 72-year-old sister of the
patient suffered from paroxysmal AF. She was admitted to an afﬁliated
hospital because of heart failure caused by restrictive cardiomyopathy
a fewmonths after presentation of her brother. Upon further clinical in-
vestigation, she had no clear signs of CTS, polyneuropathy, or autonomic
dysfunction. However, fat tissue analysis also showed amyloid (moder-
ate, 3+) [8]. The TTR concentration of amyloid in fat was 122-ng/mg fat
tissue (Nb7.5 ng/mg) [6]. TTR gene analysis identiﬁed the same TTRmu-
tation. Therefore, the sister was also diagnosed with hereditary ATTR
A45G amyloidosis. She was not interested in further clinical investiga-
tions nor in disease monitoring during follow-up.
3.3. Case 3
The daughter of Case 1 presented at the age of 56 at the outpatient
clinic with nonspeciﬁc complaints. TTR gene analysis showed the same
genotype as her father and aunt. A full diagnostic work-up for amyloid-
osis was initiated: symptoms and signs of polyneuropathy and auto-
nomic neuropathy were lacking, NT-proBNP was marginally elevated
(145 ng/L) with a normal hs-Troponin T (10 ng/l), no cardiac uptake
was visible on the 99mTc-diphosphonate bone scintigraphy, and fatA) Amyloid (4+) is red in bright light. (B) Amyloid is green in polarized light.
Fig. 2. (A–B) Anterior and posterior view 123I–SAP scintigraphy of Case 1 with slightly increased uptake in the spleen (1+). Nonspeciﬁc uptake can be seen in thyroid gland, nasopharynx,
stomach, and bladder. (C–D) Total body anterior and posterior viewof 99mTc-hydroxymethylene diphosphonate (HDP) bone scintigraphywith increased uptake in the left ventricle (3+),
increased uptake in soft tissues, and decreased uptake in the peripheral bones, indicating amyloid deposition. (E) Coronal fusion image Single Photon Emission Computed Tomography
(CT) of the HDP bone scintigraphy showing again the highly increased uptake in the left ventricle (red and yellow color of the tracer), much higher than the physiological uptake in
the bones (white CT image merged with blue color of the tracer).
21S.HC. Klaassen et al. / Cardiovascular Pathology 29 (2017) 19–22tissue analysis did not show any amyloid deposits. Therefore, at that
time, amyloidosis could not be diagnosed in the daughter, and she
was scheduled for regular follow-up as a carrier of the mutation.4. Discussion
A novel amyloidogenic TTRmutation, c.194C NG that encodes for the
primary translation product (p.A65G) and the mature protein TTR
A45G, was found in a Dutch family. Thismutationwas presented during
the International Symposium on Amyloidosis in Indianapolis in 2014
and subsequently included in the TTRmutations registry [2]. The clinical
picture of ATTR amyloidosis in the two affected family members was
foremost a late-onset cardiomyopathy [4,5,13]. 99mTc-diphosphonate
scintigraphy is currently considered useful in clinical practice and
more speciﬁc than ultrasound and CMR for noninvasive detection of
an ATTR amyloid cardiomyopathy [9].
Late-onset cardiomyopathy, frequently preceded by CTS, is typically
caused by wild-type ATTR amyloidosis [14]. Initially, this diagnosis was
considered in our index patient. However, some mutations causing he-
reditary ATTR amyloidosis are characterized by late-onset cardiomyop-
athy, such as in Afro-Caribbean patients with ATTR V122I amyloidosis
who present with cardiac failure at median age 75 (range, 50–90)
years [15]. In the Italian population with different mutations, the medi-
an age at onset of exclusive cardiomyopathy in hereditary ATTR amy-
loidosis is 70 (62–75) years [4]. A German focus with ATTR V20I
amyloidosis with exclusive cardiomyopathy and occasionally CTS has
a median age at onset of 60 years [5]. Therefore, in an elderly manwithATTR amyloid cardiomyopathy and CTS a search for a TTRmutation
is mandatory.
The TTR c.194C N G mutation is located at the end of exon 2 on the
TTR gene. A single base change, a cytosine nucleotide replaced by a gua-
nine nucleotide, is predicted to result in an amino acid change from al-
anine to glycine. Our group reported in 2014 this novel mutation to the
Website concerning TTR mutations in hereditary amyloidosis [2]. Key
features of both cases were biventricular hypertrophy and AF. Neuro-
logic manifestations were also present, albeit less prominent. In 2016,
another case with this TTR (p.A65G) mutation and amyloid cardiomy-
opathywas reported brieﬂy [13]. These observations are in line with re-
ports on all three other mutations of the same amino acid 65 of the TTR
gene: (p.A65S), (p.A65T), and (p.A65D), in which the amino acid ala-
nine (A) has been replaced by serine (S), threonine (T), and aspartic
acid (D), respectively; therefore, all four mutations on this position 65
present as a cardiomyopathy [13,16–18]. However, neurologic sequelae
can be present and should be sought for. In particular, a history of CTS—
especially bilateral — in patients presenting with restrictive cardiomy-
opathy is a strong indicator that amyloidosis may be present [19]. By
using the American College of Medical Genetics criteria for the interpre-
tation of sequence variants the current TTR c.194C N G mutation can be
classiﬁed as pathogenic [20].
Obvious limitations of this study are the small number of patients in
this family that were studied and the short follow-up period. Another
limitation is the absence of proof of actual presence of ATTR amyloid
in cardiac tissue. Only one case history of a patient with both AL and
ATTR amyloid simultaneously present in the heart has convincingly
been documented [21]. Besides, a clearly elevated serum lambda free
22 S.HC. Klaassen et al. / Cardiovascular Pathology 29 (2017) 19–22light chain was found in this case. The speciﬁcity of intense cardiac up-
take on diphosphonate scintigraphy is currently accepted as noninva-
sive evidence of the presence of ATTR amyloid in the myocardium in
patients without an elevated free light chain in the blood [9]. Exclusion
of AL amyloid is necessary but not sufﬁcient for a diagnosis of ATTR am-
yloid. The conformation of both TTR and its particularmutation in amy-
loid by direct typing using SRM-MS is requisite for typing this amyloid
as ATTR. Although the heart was not directly sampled, the imaging,
the clinical scenario, and proof of ATTR amyloid in the fat tissue are suf-
ﬁciently compelling.
Diuretic treatment is currently the only rational treatment option of
heart failure with preserved ejection fraction (HFpEF) [22]. However, in
ATTR amyloidosis the progression of polyneuropathy slows down after
tetramer-stabilizing treatment by tafamidis and diﬂunisal in which the
circulating TTR, a tetramer consisting of four identical molecules sur-
rounding in the middle a tunnel for the transport of thyroxin, is
protected against dissociation into highly amyloidogenic TTR dimers
and monomers [12,23]. The possible effect of tafamidis on progression
of ATTR amyloid cardiomyopathy is currently studied in a randomized
clinical trial, the ATTR-ACT study [24]. A second trial in which the effect
of siRNA on TTR production by the liver and thereby on progression of
hereditary ATTR polyneuropathy is currently studied in the APOLLO
trial [25]. A comparable ENDEAVOUR trial on hereditary ATTR cardio-
myopathy has been stopped recently because of unexplained increased
mortality in the treatment arm. The results of the ongoing two trials are
expected in 2018. A favorable result might have big consequences for
patients with hereditary ATTR cardiomyopathy but also for elderly
men suffering from HFpEF caused by wild-type ATTR amyloid cardio-
myopathy [26].
5. Conclusion
The novel TTR c.194C N G mutation found in this family is clinically





[1] Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human
transthyretin (TTR) variants, 2003. Amyloid 2003;10:160–84.
[2] Rowczenio D, Wechalekar A. Mutations in hereditary amyloidosis: Mutations
in Transthyretin gene (TTR). http://amyloidosismutations.com/mut-attr.php.
[Accessed September 12, 2016].
[3] Semigran MJ. Transthyretin Amyloidosis: A “Zebra” of Many Stripes. J Am Coll
Cardiol 2016;68:173–5.
[4] Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, et al. Disease proﬁle and
differential diagnosis of hereditary transthyretin-related amyloidosis with exclu-
sively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520–8.[5] Bauer R, DikowN, Brauer A, Kreuter M, Buss S, Evers C, et al. The "Wagshurst study":
p.Val40Ile transthyretin gene variant causes late-onset cardiomyopathy. Amyloid
2014;21:267–75.
[6] Bijzet J, van Gameren II, Hazenberg BP. Fat tissue analysis in the management of pa-
tients with systemic amyloidosis. In: Picken MM, Dogan A, Herrera GA, editors. Am-
yloid and related disorders: Surgical Pathology and clinical Correlations. 2nd ed.
New York: Humana Press; 2015. p. 229–48.
[7] Hazenberg BP, van Schijndel B, Bijzet J, Limburg PC, Bos R, Haagsma EB. Diagnostic
performance of transthyretin measurement in fat tissue of patients with ATTR amy-
loidosis. Amyloid 2011;18(Suppl. 1):79.
[8] Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, et al. Diag-
nostic performance of amyloid A protein quantiﬁcation in fat tissue of patients with
clinical AA amyloidosis. Amyloid 2007;14:133–40.
[9] Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Non-Biopsy
Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016;133:2404–12.
[10] Noordzij W, Glaudemans AW, van Rheenen RW, Hazenberg BP, Tio RA, Dierckx RA,
et al. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympa-
thetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging 2012;39:
1609–17.
[11] Sipe JD, BensonMD, Buxbaum JN, Ikeda S,Merlini G, SaraivaMJ, et al. Amyloidﬁbril pro-
teins and amyloidosis: chemical identiﬁcation and clinical classiﬁcation International
Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016;23:209–13.
[12] Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V,
Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a ran-
domized, controlled trial. Neurology 2012;79:785–92.
[13] Pilebro B, Suhr OB, Näsland U, Westermark P, Lindqvist P, Sundström T. 99mTc-DPD
uptake reﬂects amyloid ﬁbril composition in hereditary transthyretin amyloidosis.
Ups J Med Sci 2016;121:17–24.
[14] Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al.
Left ventricular amyloid deposition in patients with heart failure and preserved ejec-
tion fraction. JACC Heart Fail 2014;2:113–22.
[15] Dungu JN, Papadopoulou SA,Wykes K,Mahmood I, Marshall J, Valencia O, et al. Afro-
Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I
Cardiac Amyloidosis. Circ Heart Fail 2016;9:e003352.
[16] Saraiva MJ, Almeida MR, ShermanW, Gawinowicz M, Costa P, Costa PP, et al. A new
transthyretin mutation associated with amyloid cardiomyopathy. Am J Hum Genet
1992;50:1027–30.
[17] Saraiva MJ. Transthyretin mutations in health and disease. HumMutat 1995;5:191–6.
[18] Janunger T, Anan I, Holmgren G, Lövheim O, Ohlsson PI, Suhr OB, et al. Heart failure
caused by a novel amyloidogenic mutation of the transthyretin gene: ATTR
Ala45Ser. Amyloid 2000;7:137–40.
[19] Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al.
“Red-ﬂag” symptom clusters in transthyretin familial amyloid polyneuropathy. J
Peripher Nerv Syst 2016;21:5–9.
[20] Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guide-
lines for the interpretation of sequence variants: a joint consensus recommendation
of the American College of Medical Genetics and Genomics and the Association for
Molecular Pathology. Genet Med 2015;17:405–24.
[21] Mahmood S, Gilbertson JA, Rendell N, Whelan CJ, Lachmann HJ, Wechalekar AD,
et al. Two types of amyloid in a single heart. Blood 2014;124:3025–7.
[22] Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC
Guidelines for the diagnosis and treatment of acute and chronic heart failure: The
Task Force for the diagnosis and treatment of acute and chronic heart failure of
the European Society of Cardiology (ESC). Developed with the special contribution
of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200.
[23] Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing
diﬂunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA
2013;310:2658–67.
[24] Cho Y, Baranczak A, Helmke S, Teruya S, Horn EM, Maurer MS, et al. Personalized
medicine approach for optimizing the dose of tafamidis to potentially ameliorate
wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid 2015;22:175–80.
[25] Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efﬁcacy
of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819–29.
[26] González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ,
Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of
heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585–94.
